Early Stage Programs
Dermatology (unspecified)
PreclinicalResearch stage - Seeking partners
Key Facts
Indication
Dermatology (unspecified)
Phase
Preclinical
Status
Research stage - Seeking partners
Company
About Atacama Therapeutics
Atacama Therapeutics is advancing a targeted oral therapy for Acne Vulgaris, a condition affecting 40-50 million people in the US alone, where current treatments like isotretinoin have significant side effects. The company's lead program, AT-5214, is based on the novel mechanism of inhibiting sympathetic ganglion-mediated sebum production and is currently in a Phase 2 proof-of-concept trial. Founded by veterans from Extera Partners, Atacama seeks to rapidly advance its dermatology portfolio and is actively exploring partnership opportunities for its programs.
View full company profile